Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 5 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 12227581

    Anti-BCMA single domain antibodies and application thereof

    SHENZHEN PREGENE BIOPHARMA CO., LTD. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  2. US 12226490

    Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates preliminary class

    Sutro Biopharma, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  3. WO 2025027551

    VACCIN ANTI-IBV AVEC PROTÉINE DE SPICULE DE DMV/1639 HÉTÉROLOGUE

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Feb 6, 2025 · Expires Feb 1, 2045

    granted
  4. US 12215169

    Anti-complement C1s antibodies and uses thereof

    Bioverativ USA Inc. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  5. US 12209138

    Anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  6. US 12209120

    Activatable anti-VEGF scFv

    The Regents of the University of California · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  7. US 12209135

    Anti-CD45 antibodies and conjugates thereof

    Vor Biopharma Inc. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  8. US 12202883

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  9. US 12194078

    Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant

    Cartesian Therapeutics, Inc. · Granted Jan 14, 2025 · Expires Jan 9, 2045

    granted
  10. US 12187815

    Anti-inflammatory nanofibers

    Northwestern University · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  11. US 12187779

    Anti-human papillomavirus 16 E6 T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  12. US 12173078

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Dyne Therapeutics, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  13. US 12173079

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Dyne Therapeutics, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  14. US 12173058

    Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

    Mereo Biopharma 3 Limited · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  15. US 12173088

    Anti-microbial peptides

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  16. US 12172038

    Anti-coronavirus antibodies and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Svcs. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  17. US 12168054

    Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody

    Syndax Pharmaceuticals, Inc. · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  18. WO 2024249235

    CONJUGUÉS ANTICORPS-MÉDICAMENT D'AGENT DE DÉGRADATION DE BET ANTI-CD33 HUMAIN

    ABBVIE INC [US] · Granted Dec 5, 2024 · Expires Nov 30, 2044

    granted
  19. WO 2024243450

    MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET

    ABBVIE INC [US] · Granted Nov 28, 2024 · Expires Nov 23, 2044

    granted
  20. US 12144813

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  21. US 12144869

    Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates

    Sutro Biopharma, Inc. · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  22. US 12139543

    Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR

    CytomX Therapeutics, Inc. · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  23. US 12134651

    Anti-Ryk antibodies and methods of using the same

    The Regents of the University of California · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  24. US 12116574

    Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C)

    Northwestern University · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted